Dr. Dirk Thye has served as Quince Therapeutics’ Chief Executive Officer and member of its Board of Directors since May 2022. To this role, he brings more than 20 years of experience in biotechnology company creation, drug discovery, research and development, and executive leadership. Previously, Dr. Thye was Chief Executive Officer of Novosteo from September 2021 to May 2022, which was acquired by Quince Therapeutics in May 2022. Previously, from January 2016 to July 2020, he was the Executive Chairman of Geom Therapeutics, Inc., a biopharmaceutical company, and from September 2016 to January 2018, the Chief Executive Officer of Agenovir Corporation, a biopharmaceutical company. In addition, Dr. Thye has served in varied senior leadership roles, including as Chief Executive Officer, Chief Medical Officer, and Head of Clinical Development and is a Founder of seven companies, five of which were sold with excellent returns for investors. Several of the drug development programs led by Dr. Thye achieved FDA approval and he has worked in a variety of therapeutic areas such as infectious diseases, antibody/ADC discovery, oncology, inflammation, metabolic disease, and others. His corporate financing endeavors include private, IPO, and follow-on public financings resulting in over $350 million of company investment and successful exits generating billions of dollars in shareholder value. Dr. Thye holds a M.D. from the University of California, Los Angeles and a B.A. in Molecular Biology from the University of California, Berkeley. He also completed his residency in Internal Medicine at Stanford University.